As I've said before, I think your numbers are way
Post# of 72440
If we match Otezla I think $3B-$5B would be the buyout range for the company. That's why I think IPIX would prefer partnerships with an acquisition later on for more money. Big pharma is risk averse. They'd rather make 2x their money on a sure thing rather than swing for the fences.